Search This Blog

Wednesday, 28 June 2017

New bio-therapies for heart failure discussed at EACPT 2017 in Prague

The EACPT 2017 Congress was held in Prague from 24th-27th June with 566 participants from all 5 continents - 28% from beyond the European Region, from Australia to China, Japan and South Korea to the USA. The Congress included 22 sessions with Keynote Lectures on current issues for research, education and clinical practice on safe and effective use of medicines.

Heart Failure (HF) is a leading cause of death and disease in Europe. Its prevalence will continue to increase worldwide with the ageing of populations and increasing adoption of “Western” lifestyles in less developed countries. Congestive HF is the final consequence of a wide range of disorders of the heart and circulation, including hypertension, atherosclerosis, cardiomyopathy and heart valve disease.
Professor Jean-Sébastien Hulot

Despite progress in treatments with conventional medicines and devices, there remains a need for new approaches to reverse severity and progression on ventricular dysfunction.

Through an active collaboration with the Cardiovascular Research Center at Mount Sinai School of Medicine in New York (Director Prof. Hajjar) the team of Professor Jean-Sébastien Hulot in Paris is involved in the development of new targeted molecular therapies for heart failure.

In the video below you can hear Professor Hulot discuss highlights from his EACPT Prague keynote lecture on gene therapy and other new bio-therapies for heart failure.

Future EACPT Congresses:
- 2019 Stockholm
- 2021 Athens
- 2023 Rotterdam

The EACPT was founded 25 years ago and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Clinical Therapeutics, the Official Journal of EACPT.

No comments:

Post a Comment